| 2.7 0.01 (0.37%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.76 | 1-year : | 4.21 |
| Resists | First : | 3.22 | Second : | 3.6 |
| Pivot price | 2.75 |
|||
| Supports | First : | 2.58 | Second : | 2.15 |
| MAs | MA(5) : | 2.76 |
MA(20) : | 2.81 |
| MA(100) : | 2.91 |
MA(250) : | 4.08 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.1 |
D(3) : | 41.5 |
| RSI | RSI(14): 40.6  |
|||
| 52-week | High : | 8.31 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XBIT ] has closed above bottom band by 28.0%. Bollinger Bands are 53.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.75 - 2.76 | 2.76 - 2.78 |
| Low: | 2.61 - 2.62 | 2.62 - 2.64 |
| Close: | 2.68 - 2.7 | 2.7 - 2.72 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Tue, 23 Sep 2025
XBiotech (NASDAQ:XBIT) Stock Crosses Below 50 Day Moving Average - Here's What Happened - MarketBeat
Fri, 19 Sep 2025
Short Interest in XBiotech Inc. (NASDAQ:XBIT) Decreases By 45.3% - MarketBeat
Fri, 12 Sep 2025
XBiotech Inc. (NASDAQ:XBIT) Sees Significant Decline in Short Interest - MarketBeat
Mon, 08 Sep 2025
Hsbc Holdings PLC Takes $52,000 Position in XBiotech Inc. $XBIT - Defense World
Fri, 05 Sep 2025
Charles Schwab Investment Management Inc. Purchases 8,918 Shares of XBiotech Inc. $XBIT - Defense World
Mon, 16 Jun 2025
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 36.6 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 166 (K) |
| Shares Short P.Month | 422 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.6 % |
| Return on Equity (ttm) | -15.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -2.97 |
| PEG Ratio | 0 |
| Price to Book value | 0.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.29 |
| Dividend | 2.5 |
| Forward Dividend | 0 |
| Dividend Yield | 92.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|